Tags : Licensing

Takeda Signs a Licensing Agreement with Curadev for Stimulator of

Shots: Takeda enters into a licensing agreement with Curadev for its Stimulator of Interferon Genes (STING) agonist/ CRD5500 and its associated patents The focus of the agreement is to develop immuno-oncology targets, providing one day deliver transformational benefit to patients. Additionally, out-licenses its IP portfolio to Endo, Medivation & Roche Curadev’s CRD5500 is a sting […]Read More

Lilly Signs a Global Research and Licensing Agreement with Avidity

Shots: Avidity to receive $20M upfront, $15M equity investment, $405M as development, regulatory & commercial milestones for each target and royalties on sales. Lilly to get WW rights to develop and commercialize the products to be developed in immunology and other indications The companies will develop & commercialize RNA-based therapies with the combination of tissue […]Read More

Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to

Shots: Codexis to receive $3M milestone and NHSc to get exclusive WW rights to develop and commercialize Codexis’s CDX-6114 for phenylketonuria (PKU) In 2017, Codexis & NHSc collaborated to develop CDX-6114 using Codexis’ CodeEvolver protein engineering platform paying $14M upfront and future milestones and granted an option to license for CDX-6114 to NHSc  Codexis’s CDX-6114 […]Read More